[go: up one dir, main page]

BG60933B2 - Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него - Google Patents

Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него Download PDF

Info

Publication number
BG60933B2
BG60933B2 BG098632A BG9863294A BG60933B2 BG 60933 B2 BG60933 B2 BG 60933B2 BG 098632 A BG098632 A BG 098632A BG 9863294 A BG9863294 A BG 9863294A BG 60933 B2 BG60933 B2 BG 60933B2
Authority
BG
Bulgaria
Prior art keywords
clmf
protein
leo
ser
cells
Prior art date
Application number
BG098632A
Other languages
Bulgarian (bg)
English (en)
Inventor
Richard Chizzonite
Maurice Gately
Ulrich Gubler
Jeffrey Hulmes
Yu-Ching Pan
Frank Podlaski
Alvin Stern
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60933(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of BG60933B2 publication Critical patent/BG60933B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG098632A 1989-12-22 1994-03-01 Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него BG60933B2 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45570889A 1989-12-22 1989-12-22
US52093590A 1990-05-09 1990-05-09
US57228490A 1990-08-27 1990-08-27

Publications (1)

Publication Number Publication Date
BG60933B2 true BG60933B2 (bg) 1996-06-28

Family

ID=27412641

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098632A BG60933B2 (bg) 1989-12-22 1994-03-01 Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него

Country Status (11)

Country Link
EP (4) EP0433827B1 (da)
JP (2) JP3238418B2 (da)
AT (4) ATE369383T1 (da)
AU (2) AU6834990A (da)
BG (1) BG60933B2 (da)
CA (3) CA2572802A1 (da)
DE (4) DE69034244T2 (da)
DK (4) DK0790255T3 (da)
HU (1) HU211879A9 (da)
IE (1) IE904694A1 (da)
NZ (1) NZ236545A (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0375045A1 (en) * 1988-12-22 1990-06-27 Duphar International Research B.V New annelated indole derivatives
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0850951A4 (en) * 1996-06-04 2001-04-11 Juridical Foundation NEW FELINE CYTOKINE PROTEIN
JP2001503258A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド 遺伝子発現および搬送系および用途
JP2001503257A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Ｉｌ―１２遺伝子発現および送達系および使用
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
JP2002241398A (ja) * 1997-06-03 2002-08-28 Chemo Sero Therapeut Res Inst 新規なイヌサイトカインタンパク質
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
WO2001018051A2 (en) * 1999-09-09 2001-03-15 Schering Corporation Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
AU2005202420B2 (en) * 1999-09-09 2008-08-07 Merck Sharp & Dohme Corp. Mammalian cytokines; related reagents and methods
EP3184637A1 (en) * 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
EP1836294A4 (en) 2004-12-21 2009-06-17 Centocor Inc ANTI-IL-12 ANTIBODIES, EPITOPES, COMPOSITIONS, METHODS AND USES
CA2635618C (en) 2005-12-30 2015-10-06 Merck Patent Gesellschaft Mit Beschraekter Haftung Interleukin-12p40 variants with improved stability
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
US7891807B2 (en) * 2009-06-11 2011-02-22 Ana Nichole Mansuy Decorative eyeglass temples
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
US10189151B2 (en) 2016-11-14 2019-01-29 Snap-On Incorporated Compact head body hammer
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
JP7421500B2 (ja) 2018-05-18 2024-01-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
WO2021234634A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0441900B1 (en) * 1988-11-10 1996-07-17 Genetics Institute, Inc. Natural killer stimulatory factor

Also Published As

Publication number Publication date
NZ236545A (en) 1993-04-28
DE69034247D1 (de) 2007-09-06
ATE368112T1 (de) 2007-08-15
EP0790308A1 (en) 1997-08-20
JP3238418B2 (ja) 2001-12-17
DE69034249D1 (de) 2007-09-20
JP2002167400A (ja) 2002-06-11
EP0790255A3 (en) 2000-03-01
IE904694A1 (en) 1991-07-17
JPH05294999A (ja) 1993-11-09
DE69034244D1 (de) 2007-08-16
CA2032653A1 (en) 1991-06-23
AU674363B2 (en) 1996-12-19
EP0790309A1 (en) 1997-08-20
DE69034244T2 (de) 2008-04-03
DK0790309T3 (da) 2007-11-05
AU6834990A (en) 1991-06-27
ATE366311T1 (de) 2007-07-15
EP0790255A2 (en) 1997-08-20
IE990006A1 (en) 2000-11-01
EP0433827B1 (en) 1998-03-04
DK0790255T3 (da) 2007-11-26
CA2346997A1 (en) 1991-06-23
HU211879A9 (en) 1995-12-28
ATE163675T1 (de) 1998-03-15
DE69034247T2 (de) 2008-04-17
EP0790309B1 (en) 2007-07-25
JP3375949B2 (ja) 2003-02-10
EP0433827A2 (en) 1991-06-26
CA2572802A1 (en) 1991-06-23
DE69032086D1 (de) 1998-04-09
DK0790308T3 (da) 2007-10-08
CA2346997C (en) 2007-02-20
ATE369383T1 (de) 2007-08-15
DE69034249T2 (de) 2008-05-29
EP0790308B1 (en) 2007-07-04
DK0433827T3 (da) 1998-09-28
IE990007A1 (en) 2000-11-01
CA2032653C (en) 2002-05-28
AU5471294A (en) 1994-06-09
IE990005A1 (en) 2000-11-01
EP0790255B1 (en) 2007-08-08
DE69032086T2 (de) 1998-09-17
EP0433827A3 (en) 1992-07-01

Similar Documents

Publication Publication Date Title
BG60933B2 (bg) Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него
US5780597A (en) Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US5286654A (en) Detection and purification of activin polypeptide
KR0150060B1 (ko) 사람 인터루킨-5에 대한 인간화 모노클로날 항체의 고안, 클로닝 및 발현
IE890207L (en) Amphiregulin: a novel bifunctional growth modulating glycoprotein
KR20080105111A (ko) 항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
NZ264003A (en) Interleukin-12 receptor protein and dna, immunoglobulin capable of binding the protein and pharmaceutical compositions
WO1992000376A1 (en) Mast cell growth factor
IE19990005A1 (en) Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor
IE19990006A1 (en) Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
WO1993007271A1 (en) Osteoclast colony stimulating factor (o-csf)
AU775308B2 (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
IE85054B1 (en) Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor
WO1990014351A1 (en) Hematopoietic growth factor derived form t lymphocytes and methods of use therefor
IE85055B1 (en) Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
IE19990007A1 (en) Cytotoxic Lymphocyte Maturation Factor
IE84906B1 (en) Cytotoxic Lymphocyte Maturation Factor
JPWO2000035956A1 (ja) 抗ヒトｖｅｇｆモノクローナル抗体
MXPA00001234A (en) Heparin-binding growth factor (hbgf) polypeptides